These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 26842912)
1. Immune regulation of canine tumour and macrophage PD-L1 expression. Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912 [TBL] [Abstract][Full Text] [Related]
2. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
3. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines. Owaki R; Deguchi T; Konnai S; Maekawa N; Okagawa T; Hosoya K; Kim S; Sunaga T; Okumura M Vet Comp Oncol; 2023 Jun; 21(2):279-290. PubMed ID: 36802270 [TBL] [Abstract][Full Text] [Related]
4. Spleen-derived IFN-γ induces generation of PD-L1 Langereis JD; Pickkers P; de Kleijn S; Gerretsen J; de Jonge MI; Kox M J Leukoc Biol; 2017 Dec; 102(6):1401-1409. PubMed ID: 28974543 [TBL] [Abstract][Full Text] [Related]
5. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036 [TBL] [Abstract][Full Text] [Related]
6. Checkpoint molecule expression by B and T cell lymphomas in dogs. Hartley G; Elmslie R; Dow S; Guth A Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929 [TBL] [Abstract][Full Text] [Related]
7. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996 [TBL] [Abstract][Full Text] [Related]
8. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356 [TBL] [Abstract][Full Text] [Related]
10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
11. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758 [TBL] [Abstract][Full Text] [Related]
12. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α. Hartley G; Regan D; Guth A; Dow S Cancer Immunol Immunother; 2017 Apr; 66(4):523-535. PubMed ID: 28184968 [TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells. Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878 [TBL] [Abstract][Full Text] [Related]
15. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Jiang C; Yuan F; Wang J; Wu L Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596 [TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells promote CD169 Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052 [TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Ligand 1 Expression in Canine Cancer. Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]